SAN DIEGO, Calif.--Acadia Pharmaceuticals here, a biotech company engaged in development and use of high-throughput screening technologies for drug discovery, announced the appointment of Leonard Bormann to the position of CEO. Bormann left the post of vice-president of business development at Allergan, where he worked for 14 years.

Mark Brann, Acadia's current CEO who will continue in his roles as chief scientific officer and president, said Bormann's appointment is key for Acadia. "As a lead discovery company, we need this kind of comprehensive expertise," he said.